Literature DB >> 3255916

A novel means of comparing the bioequivalence of two formulations of tripotassium dicitrato bismuthate (De-Noltab).

S B Coghill1, A N Shepherd.   

Abstract

Tripotassium dicitrato-bismuthate (TDB) has a topical action in the upper gastrointestinal tract. Absorption is minimal and the blood levels are therefore irrelevant to the assessment of bioavailability. TDB is however detectable in the stomach and duodenum by conventional electron microscopy. Following oral administration of two different formulations of TDB tables to patients attending a gastroscopy clinic, duodenal biopsies were obtained and examined by electron microscopy. The amount of electron dense drug precipitate was quantified. No difference could be detected between the two formulations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3255916      PMCID: PMC2429014          DOI: 10.1136/pgmj.64.756.761

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Acid reduction or mucosal protection for peptic ulcer?

Authors: 
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

2.  Controlled trial comparing De-Nol tablets with De-Nol liquid in treatment of duodenal ulcer.

Authors:  I Hamilton; A T Axon
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

3.  Interaction of tripotassium dicitrato bismuthate with macrophages in the rat and in vitro.

Authors:  R L Soutar; S B Coghill
Journal:  Gastroenterology       Date:  1986-07       Impact factor: 22.682

  3 in total
  1 in total

1.  Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations.

Authors:  Quan Zhou; Zou-Rong Ruan; Hong Yuan; Bo Jiang; Dong-Hang Xu
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.